IT CI

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Application of: Ulrich KLAR et al.

Serial No.: 09/913,163 Group Art Unit: 1625

Filed: December 7, 2001 Examiner: Binta M. Robinson

For: EPOTHILON DERIVATIVES, METHOD FOR THE PRODUCTION AND THE USE

THEREOF AS PHARMACEUTICALS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

	der 37 C.F.R. § 1.97(b), no fee or statement is required for filing this information closure statement is filed:						
		three months of the filing date of a national application other than a CPA § 1.53(d);					
		within three months of the actual filing date of the national phase of a PCT application; OR					
	before RCE)	e the mailing of a first substantive office action (including after filing of an					
\boxtimes	Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the period specified in 37 C.F.R. § 1.97(b), but before the mailing date of:						
	\boxtimes	a final rejection under 37 C.F.R. 1.113;					
		termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR					
		a notice of allowance under 37 C.F.R. § 1.311; and					

	is acc	is accompanied by:			
	\boxtimes	the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR			
		a check covering the fee of \$ under 37 C.F.R. § 1.17(p).			
		F.R. § 1.97(d), this information disclosure statement is filed after the mailing ollowing actions which have not been withdrawn:			
		a final action under 37 C.F.R. § 1.113;			
		termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR			
		a notice of allowance under 37 C.F.R. § 1.311;			
Al	ND is filed	on or before payment of the issue fee; AND is accompanied by:			
		the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p).			
Statements	s Under 37	C.F.R. 1.97(e)			
		Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or			
		No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.			
Cited Mate	erials				
	ancest	s of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).			
		s of materials listed but not attached were cited in an international search dated			
\boxtimes	Copies	s of the materials listed are attached (except for the foregoing).			

Non-l	English	Language References					
		An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).					
		A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:					
		 X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document 					
		A = document defining the general state of the art					
		O = non-written disclosure P = intercalated document					
		T = document cited to understand the theory or principle underlying the invention					
		E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date					
		D = cited in the application					
		L = cited for another reason & = publication of member of same patent family					
		paonoation of member of same patent failing					
		Translation of other relevant information on foreign search report					
		[insert necessary translation here]					
Other	Informa	<u>ation</u>					
Pavme	ent of Fa	ees Due (If Any):					
		ck for \$ covering the fee identified above is attached.					
	Please	Please charge to Deposit Account No. 13-3402 \$ for the fee identified above.					

 \boxtimes The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Csaba Henter, Reg. No. 50,908 Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: SCH-1814

Date: November 3, 2004

CH:pdr

Sheet

(use as many sheets as necessary)

of 2

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031 Approved for use through 10/31/2002. OMB 0651-0031 Approved for use through 10/31/2002. OMB 0651-0031 ONB opersons are required to expend to a collection of information unless it contains a valid OMB control number. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 199 SENT & TRADE Substitute for form 1449A/PTO Complete if Known pplication Number 09/913,163 INFORMATION DISCLOSURE December 7, 2001 Filing Date STATEMENT BY APPLICANT First Named Inventor Ulrich Klar

Group Art Unit

Examiner Name

Attorney Docket Number

1625

SCH-1814

Binta M. Robinson

		U.S. Pat	tent Document		PATENT DOCUM			
Examiner Initials *	r Cite No.1	Number	Kind Code ² (if known)	Name of of	Patentee or Applicant Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	<u> </u>	6,730	,699		Li et al.			
		ļ						
	-	 			· · · · · · · · · · · · · · · · · · ·			
		<u> </u>						
				FO	REIGN PATENT I	DOCUMENTS		
Examiner Initials*	Cite No.1	Fore Office ³	eign Patent Do Number⁴		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures	_
			200401		App		Appear	Тө
		wo	200401	5000				
		-			-	+		
		_	 					
		+	 		1			
			 					
_						1	†	
			Ì	<u> </u>				

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

Applicant is to place a check mark if the English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please	type	а	DILLS	Sign	(+)	ahizni	thic	DOX

PTO/SB/08A (08-00) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1990 persons are required ed to respond to a collection of information unless it contains a valid OMB control number

Substitute	for form 1449A/PT(0	THAD	Complete if Known			
INITO	DRAATION	DIG	CL OCUDE	Application Number	09/913,163		
	· · · · · · · · · · · · · · · · · · ·		CLOSURE	Filing Date	December 7, 2001		
STATEMENT BY APPLICANT				First Named Inventor	Ulrich Klar		
				Group Art Unit	1625		
((use as many she	ets as	necessary)	Examiner Name	Binta M. Robinson		
Sheet	2	of	2	Attorney Docket Number	SCH-1814		

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
		Ca 127:268036, "Water soluble paclitaxel prodrugs", Li et al., U.S. Patent 6730699.	
		Ca 140:176348, "Transposon-based transformation system encoding a transposase and uses for mutagenesis", Julien et al., WO 2004015088.	
			

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.